Found 30 results
Author Title Type [ Year(Asc)]
Filters: Author is [...]  [Clear All Filters]
2008
S. Mehendale, van Lunzen, J., Clumeck, N., Rockstroh, J., Vets, E., Johnson, P. R., Anklesaria, P., Barin, B., Boaz, M., Kochhar, S., Lehrman, J., Schmidt, C., Peeters, M., Schwarze-Zander, C., Kabamba, K., Glaunsinger, T., Sahay, S., Thakar, M., ,, and Heald, A., “A Phase 1 Study to Evaluate the Safety and Immunogenicity of a Recombinant HIV Type 1 Subtype C Adeno-Associated Virus Vaccine”, AIDS Research and Human Retroviruses, vol. 24, pp. 873-880, 2008.
B. Leyland-Jones, Ambrosone, C., Bartlett, J., Ellis, M., Enos, R., Raji, A., Pins, M., Zujewski, J., Hewitt, S., Forbes, J., Abramovitz, M., Braga, S., Cardoso, F., Harbeck, N., Denkert, C., Jewell, S., Group, B. Internatio, and , “Recommendations for Collection and Handling of Specimens from Group Breast Cancer Clinical Trials”, J Clin Oncol, vol. 26, pp. 5638-5644, 2008.
J. W, FN, N., O, A., G, O. Manyonyi, J, B., A, N., F, B., K, B., H, O., S, W., L, M., W, W., J, O., M, O., J, I., J, N. - A., C, K., ,, Smith, C., Barin, B., Dally, L., ,, and Kaleebu, P., “Safety and Immunogenicity of Recombinant Low-Dosage HIV-1 A Vaccine Candidates Vectored by Plasmid pTHr DNA or Modified Vaccinia Virus Ankara (MVA) in Humans in East Africa”, Vaccine, vol. 26, pp. 2788-2795, 2008.
J. W, FN, N., O, A., G, O. Manyonyi, J, B., A, N., F, B., K, B., H, O., S, W., L, M., W, W., J, O., M, O., J, I., J, N. - A., C, K., ,, Smith, C., Barin, B., Dally, L., ,, and Kaleebu, P., “Safety and Immunogenicity of Recombinant Low-Dosage HIV-1 A Vaccine Candidates Vectored by Plasmid pTHr DNA or Modified Vaccinia Virus Ankara (MVA) in Humans in East Africa”, Vaccine, vol. 26, pp. 2788-2795, 2008.
1998
B. S. Graham, McElrath, M. J., Connor, R. I., Schwartz, D. H., Gorse, G. J., Keefer, M. C., Mulligan, M. J., Matthews, T. J., Wolinsky, S. M., Montefiori, D. C., Vermund, S. H., Lambert, J. S., Corey, L., Belshe, R. B., Dolin, R., Wright, P. F., Korber, B. T., Wolff, M. C., Fast, P., and , “Analysis of Intercurrent Human Immunodeficiency Virus Type 1 Infections in Phase I and II Trials of Candidate AIDS Vaccines”, J Infec Dis, vol. 177, pp. 310-319, 1998.